The use of IMT has been shown to have inherent benefits for certain uveitic entities. In this example, the patients have the same disease, multifocal choroiditis with panuveitis (MFC-PU), which has been treated over several years. For patients with MFC-PU, the use of IMT has been associated with an 80% decrease in posterior segment complications. Patient A (top 2 images; from left to right: left fundus, right fundus) received triple therapy with mycophenolate mofetil (CellCept), cyclosporine (Neoral), and prednisone upon diagnosis, and has had adequate preservation of posterior pole function with good central visual outcome. Conversely, Patient B (bottom 2 images; from left to right: left fundus, right fundus), who was treated with oral corticosteroids and periodic posterior sub-Tenon triamcinolone injections, developed bilateral choroidal neovascular membranes and became legally blind.